SFSamoshchenkova I. F.

Samoshchenkova I. F.

*This is an algorithmically generated author record based on publicly available information.

Samoshchenkova I. F. has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Problems and Solutions of Pharmaceutical Packaging in Bulk

    by R. Yu. Garankina, V. V. Ryazhenov, E. A. Maksimkina, V. S. Fisenko, A. V. Alekhin, V. V. Tarasov, K. A. Chizhov, I. F. Samoshchenkova, N. Yu. Behorashvili, E. R. Zakharochkina

    To date, pharmaceutical activities in the manufacture of medicines in a pharmacy, intra-pharmacy packaging of registered medicines in Russia and the countries of the Eurasian Economic Union (EAEU), is one of the priorities of regulatory authorities in order to improve drug supply.The aim. To study the current state of legal regulation of the circulation of medicines “in bulk” and the possibility of their packaging in a pharmacy.Materials and methods. To solve the tasks set, the methodology of system analysis in the field of drug provision, content analysis of documents regulating the sphere of circulation of drugs was used. The regulatory framework of the study was the legislative and by-laws regulating the sphere of circulation of medicines of the Russian Federation and the common market of the EAEU. The search for regulatory legal acts was carried out in the Directory of the legal system “ConsultantPlus”. In the course of the research, a set of scientific methods was used such a systematic, logical, structural and comparative.Results. The article consider the issues of legal regulation of the circulation of medicines “in bulk” in the pharmaceutical market. The current state of the legislative and regulatory framework has been studied and the problems of legal regulation of packaging of medicicnes “in bulk” in pharmacies have been identified. The article also focuses on the general problem of compliance with modern packaging requirements for medicines compounded in pharmacy. The possibility of introducing a new concept of “Pharmacy packaging” into Federal Law No. 61-FZ dated April 12, 2010 “On the circulation of medicines” is considered. The approaches developed in world practice to the regulation of issues related to the packaging of drugs “in bulk” in pharmacy are considered. Based on the results of the study, the possibilities have been identified and ways to improve the mechanisms of state regulation have been proposed.Conclusion. Packaging of medicines “in bulk” will increase the effectiveness of individual drug therapy, optimize and reduce the cost of circulation of budget funds, pharmacies and citizens.


  • ORPHAN DISEASES: REGULATION OF DRUG PROVISION FOR PATIENTS IN RUSSIA

    by Garankina R.Y., Samoshchenkova I. F., Zaharochkina E.R., Kondratova D. V., Behorashvili N

    In conditions of budget deficit, the issues of drug provision for patients suffering from life-threatening and chronic progressive rare (orphan) diseases require constant monitoring by regulatory authorities. In this regard, the purpose of the work was to analyze the main aspects of the legal regulation of drug provision for persons with rare (orphan) diseases. The lack of funds in the regions which could fully meet the needs of patients with rare (orphan) diseases in the provision of medicines, served as a weighty argument for the launch of the state federal program for high-costnosologies and the centralization of public procurement of medicines. The key tool for improving drug care was the approval of lists of orphan diseases and the introduction of the federal register of patients eligible for preferential drug provision into the unified information and analytical healthcare system. An important and defining moment of federalization of procurement of medicines was the creation of a federal state institution under the Ministry of Health "Federal Center for Planning and Organization of Drug Provision for Citizens". The main additional mechanism and alternative solution for providing medicines to children under 18 with severe life-threatening and chronic diseases, including rare (orphan) diseases, was the charitable support fund "Circle of Good" created by presidential decree. The financial and organizational approach and the decision of the regulator to federalize the procurement of orphan medicines under the high-cost nosology program makes it possible to increase the equal availability of medicines to persons with rare (orphan) diseases in all subjects of the Russian Federation and to reduce the costs of budget allocations.


  • MODELING OF THE SELECTION OF MEDICINES IN THE LIST OF VITAL AND ESSENTIAL MEDICINES BY QUALITATIVE INDICATORS

    by Samoshchenkova I.F., Filina I.A., Garankina R.Y., Ustinova L.P., Yershova S.I., Kolesnikov A.S.

    The variety of medicines in circulation on the pharmaceutical market causes the problem of rational choice of medicines for their inclusion in restrictive lists. To form a list of vital and essential medicines (VED), the regulator uses certain rules approved at the legislative level. It should be noted that the determining factor for rational therapy is the evaluation of medicine in terms of the ratio "efficacy / safety". Based on this, the purpose of this study was to develop the process of graphical modeling process when the medicine is included in the VED list in terms of its qualitative characteristics – efficiency and safety. The source was data from Appendix No. 6 "Integral scales of the comprehensive evaluation of a medicinal product" to the " Rules for the formation of lists of medicines for medical use and the minimum range of medicines necessary for the provision of medical care". The developed modeling process eliminates the need to evaluate all indicators in case of obtaining a negative qualifying result in its initial parts, eliminates the need for mathematical operations, and competently ranks the criteria of the selected medicine to the comparison medicine, thus allowing to choose the most preferable option in the case of evaluating several medicines of a single action and significantly speeds up the procedure for a comprehensive assessment of medicine. The model enables the regulator to have a clearer decision-making procedure for the formation of a defining restrictive list of VED in the Russian healthcare system. Thus, the proposed graphical model makes it possible to simplify and, thereby, expedite the process of including medicines in the list of vital and essential medicines of VED.